mProX™ Human EPOR Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

EPOR (erythropoietin receptor) has been studied in various medical contexts. In lung adenocarcinoma (LUAD), EPOR expression has been found to be down-regulated at the mRNA levels and up-regulated at the protein levels, indicating inconsistency between mRNA and protein levels. EPOR has also been associated with oxidative stress-related genes and prognosis in LUAD patients, suggesting its potential as a prognostic marker. In B-cell acute lymphoblastic leukemia (B-ALL), EPOR has been detected in gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus, and its detection rates have been optimized using bioinformatics analysis workflows. In Philadelphia chromosome-like B-ALL, a surrogate molecular approach involving EPOR has been proposed for the detection of this high-risk genetic subtype. In memory and learning, EPOR expression has been induced in memory-relevant brain areas, and exogenously applied EPO (erythropoietin) has been found to promote remote memory consolidation. In traumatic brain injury (TBI), recombinant EPO has been shown to induce oligodendrocyte progenitor cell (OPC) proliferation, potentially enhancing remyelination and promoting myelination after TBI.